Inhibrx Biosciences (INBX) Debt Ratio (2023 - 2025)

Inhibrx Biosciences' (INBX) quarterly Debt Ratio came in at 0.69 in Q4 2025, up 21.94% on a QoQ basis from 0.56 in Q3 2025.

Inhibrx Biosciences (INBX) Debt Ratio (2023 - 2025) Analysis & Trends

Inhibrx Biosciences (INBX) has 2 years of Debt Ratio data on file, last reported at 0.69 in Q4 2025.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.69 in Q4 2025; TTM through Dec 2025 was 0.69, a N/A change from a year earlier, with the FY2025 full-year figure at 0.69, changed N/A from the prior year.
Debt Ratio for Q4 2025 stood at 0.69, up from 0.56 in the prior quarter.
Over the last five years, Debt Ratio for INBX reached as high as 0.69 in Q4 2025 and fell as low as 0.41 in Q1 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Inhibrx Biosciences	1.32 Bn	1.32 Bn	-	0.69

Historic Data

Download Data

Date	Value
Dec 31, 2025	0.69
Sep 30, 2025	0.56
Jun 30, 2025	0.47
Mar 31, 2025	0.41
Dec 31, 2023	0.67